Remove Diagnostic Imaging Remove Radiation Oncology Remove Radiopharmaceuticals
article thumbnail

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. Louis is unique for radiopharmaceutical therapy patient triage, Prasad said. Also be mindful of design requirements in the U.S.;

article thumbnail

The rise of theranostics: Part 3 -- What is a theranostics center?

AuntMinnie

With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Visit TTG Imaging Solutions at ASTRO 2021 Annual Meeting

TTG Imaging Solutions

The American Society for Radiation Oncology 2021 Annual Meeting: October 24 – 26 TTG Imaging Solutions is proud to be exhibiting at the American Society for Radiation Oncology Annual Meeting in Chicago, IL. Be sure to visit us and experience our brand new 30′ x 30′ booth.

article thumbnail

TTG Imaging Solutions Acquires Digirad Health from Star Equity Holdings

TTG Imaging Solutions

Enhances TTG’s continued commitment to offer a full spectrum of high-quality and cost-effective service solutions in the cardiology and radiation oncology markets PITTSBURGH, PA (May 5, 2023) – TTG Imaging Solutions, LLC (TTG) announced today the acquisition of Digirad Health, Inc., headquartered in Suwanee, GA.

Imaging 52
article thumbnail

Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

Imaging Technology

We are pleased to present these results from the LIGHTHOUSE study to the radiation oncology community at ASTRO,” said David E. Chief Executive Officer of Blue Earth Diagnostics. The findings were discussed in a poster Q&A session at the 2023 ASTRO Annual Meeting on October 3, 2023 ,“ Diagnostic Performance of 18 F-rhPSMA-7.3

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval. Since the U.S.